Drug intelligence / Profile preview

docetaxel + pegvorhyaluronidase alfa

Development stage: Discontinued
Lead developer: Halozyme
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous

Overview

Docetaxel + pegvorhyaluronidase alfa is a combination therapy that pairs a standard cytotoxic chemotherapy agent (docetaxel) with an enzyme that degrades hyaluronan (HA) in the tumor microenvironment. Pegvorhyaluronidase alfa (PVHA/PEGPH20) enzymatically degrades hyaluronan in the tumor microenvironment, which is thought to improve vascular perfusion and enhance intratumoral delivery of anticancer agents like docetaxel. This combination was investigated for the treatment of stage IIIB/IV non-small cell lung cancer (NSCLC).

Other names: pegvorhyaluronidase alfa combined with docetaxel

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on docetaxel + pegvorhyaluronidase alfa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on docetaxel + pegvorhyaluronidase alfa.

Explore the full profile